COGNITION THERAPEUTICS INC. - COMMON STOCK

Cognition Therapeutics Awarded $2.14 Million in Supplemental Grant Funding from NIA to Support SEQUEL Clinical Trial

27 Sep 2022 07:32:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Participation in September Investment Conferences

06 Sep 2022 07:32:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

09 Aug 2022 07:00:01 By Nasdaq GlobeNewswire

Cognition Therapeutics Presents New Proteomic Data on Effect of CT1812 Treatment on Normalization of Disrupted Alzheimer’s Disease Processes

04 Aug 2022 16:02:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

03 Aug 2022 16:05:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Presenting New Analyses from Ongoing Clinical Trial of CT1812 in Mild-to-Moderate Alzheimer’s Disease

19 Jul 2022 08:00:02 By Nasdaq GlobeNewswire

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

23 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference

08 Jun 2022 07:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation

02 Jun 2022 16:01:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference

13 May 2022 07:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

11 May 2022 07:00:01 By Nasdaq GlobeNewswire

CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

04 May 2022 17:54:44 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

04 May 2022 16:01:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD

03 May 2022 08:00:03 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration

25 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

25 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Cognition Therapeutics Announces Participation in 21st Annual Needham Virtual Healthcare Conference

06 Apr 2022 07:30:00 By Nasdaq GlobeNewswire

Cognition Therapeutics Reports Year End 2021 Financial Results and Provides Business Update

30 Mar 2022 07:00:00 By Nasdaq GlobeNewswire

Cognition Therapeutics to Report Fourth Quarter and Full Year 2021 Results

22 Mar 2022 08:00:03 By Nasdaq GlobeNewswire

Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer’s Disease at AD/PD 2022

10 Mar 2022 07:30:00 By Nasdaq GlobeNewswire